ELVN vs. RNA, ACLX, OGN, ZLAB, RARE, SWTX, AKRO, ALVO, RYTM, and MRUS
Should you be buying Enliven Therapeutics stock or one of its competitors? The main competitors of Enliven Therapeutics include Avidity Biosciences (RNA), Arcellx (ACLX), Organon & Co. (OGN), Zai Lab (ZLAB), Ultragenyx Pharmaceutical (RARE), SpringWorks Therapeutics (SWTX), Akero Therapeutics (AKRO), Alvotech (ALVO), Rhythm Pharmaceuticals (RYTM), and Merus (MRUS). These companies are all part of the "pharmaceutical products" industry.
Enliven Therapeutics vs.
Enliven Therapeutics (NASDAQ:ELVN) and Avidity Biosciences (NASDAQ:RNA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, community ranking, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.
Avidity Biosciences received 156 more outperform votes than Enliven Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Enliven Therapeutics an outperform vote while only 69.01% of users gave Avidity Biosciences an outperform vote.
Enliven Therapeutics has a net margin of 0.00% compared to Avidity Biosciences' net margin of -2,772.45%. Avidity Biosciences' return on equity of -27.66% beat Enliven Therapeutics' return on equity.
Enliven Therapeutics has higher earnings, but lower revenue than Avidity Biosciences. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Avidity Biosciences, indicating that it is currently the more affordable of the two stocks.
Enliven Therapeutics has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500. Comparatively, Avidity Biosciences has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500.
Enliven Therapeutics presently has a consensus price target of $38.75, indicating a potential upside of 72.53%. Avidity Biosciences has a consensus price target of $66.69, indicating a potential upside of 100.28%. Given Avidity Biosciences' higher possible upside, analysts plainly believe Avidity Biosciences is more favorable than Enliven Therapeutics.
95.1% of Enliven Therapeutics shares are owned by institutional investors. 29.2% of Enliven Therapeutics shares are owned by company insiders. Comparatively, 3.7% of Avidity Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
In the previous week, Avidity Biosciences had 12 more articles in the media than Enliven Therapeutics. MarketBeat recorded 26 mentions for Avidity Biosciences and 14 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 0.80 beat Avidity Biosciences' score of 0.44 indicating that Enliven Therapeutics is being referred to more favorably in the media.
Summary
Enliven Therapeutics beats Avidity Biosciences on 10 of the 18 factors compared between the two stocks.
Get Enliven Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Enliven Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ELVN) was last updated on 3/25/2025 by MarketBeat.com Staff
Buy ELVN Stock Free ELVN Stock Alerts